Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4379490 | 0.93 | ATM (0.39) | ATML3MBTL1SCN9AADAM17MMP1 | |
| SCHEMBL8225081 | 0.89 | RORC (0.43) | ATML3MBTL1SCN9AADAM17MMP1 | |
| SCHEMBL4384704 | 0.88 | L3MBTL1 (0.45) | ATML3MBTL1SCN9AADAM17MMP1 | |
| SCHEMBL13589015 | 0.87 | CYP3A4 (0.43) | ATML3MBTL1ADAM17MMP1GAA | |
| SCHEMBL4385458 | 0.87 | PKM (0.39) | ATML3MBTL1SCN9AADAM17MMP1 | |
| SCHEMBL4383813 | 0.85 | RORC (0.43) | ATML3MBTL1SCN9AALDH1A1LMNA | |
| SCHEMBL4379092 | 0.84 | MRGPRX4 (0.45) | L3MBTL1GAAALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL4382619 | 0.84 | PKM (0.42) | ATML3MBTL1ALDH1A1PKMRORC | |
| SCHEMBL4382363 | 0.83 | GPBAR1 (0.47) | ATMGAACYP3A4ALDH1A1LMNA | |
| SCHEMBL4380262 | 0.83 | LMNA (0.48) | L3MBTL1ADAM17MMP1CYP3A4GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | ATM 4309/4885L3MBTL1 2099/4885SCN9A 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.